KTTA

Pasithea TherapeuticsA

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-06-02

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

25%

Probability

Target price

$1.40

+117.1% vs current

Most likely

Base case

45%

Probability

Target price

$0.75

+16.3% vs current

B-

Bear case

30%

Probability

Target price

$0.30

-53.5% vs current

AI sentiment snapshot

Latest data as of 2026-04-15

AI commentary

Primary-source evidence supports a cautious monitoring stance rather than an aggressive bullish call. The 10-K provides real clinical and balance-sheet anchors, but forward visibility is still limited to early-stage execution milestones and management-planned interim updates, while the February 2026 Nasdaq notice adds a nearer-term technical overhang [#10-K-2026-03-30] [#8-K-2026-02-20]. The peer set remains provisional and mostly market-cap based, so the thesis should be treated as tentative optionality backed by cash rather than a peer-validated rerating setup.

RankAlpha Sentiment Codex - 2026-04-15

Open full AI memo

Evidence flagged

small-cap biotech peer set is too weak or includes unrelated comparators for a standard-conviction report

Impact

tentative

Confidence

AI events

2026-08-19eventNasdaq bid-price cure decision remains the clearest near-term stock eventHigh impact

KTTA disclosed on February 20, 2026 that Nasdaq notified the company it was below the $1.00 minimum bid requirement and gave it until August 19, 2026 to regain compliance; failure to cure can push the company toward a reverse split, an extension request, or delisting proceedings, making this the highest-visibility near-term equity catalyst [#8-K-2026-02-20].

2026-12-31catalystPAS-004 advanced cancer updates are expected through 2026High impact

The 2025 10-K says Pasithea has completed dose escalation through cohort 8 in the first-in-human advanced cancer study, has not reached MTD, has seen no DLTs in assessed cohorts, and plans to provide additional interim data throughout 2026; positive PK, tolerability, or early efficacy signals could help sentiment, but the program remains early and data risk is high [#10-K-2026-03-30].

2026-12-31catalystAdult NF1 Part A completion is a 2026 execution checkpointHigh impact

The 2025 10-K says Pasithea initiated the Phase 1/1b adult NF1 trial in May 2025, dosed the first patient in July 2025, has enrolled and dosed three patients in each of the initial four Part A cohorts, and expects to complete Part A by the end of 2026 before moving to Part B in 2027 following FDA dialogue; clean execution would support the platform narrative, while slippage would reinforce a monitoring-only view [#10-K-2026-03-30].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-04-15 • Updated nightlySource: Internal modelMethodology